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ABSTRACT 
An important goal of gene therapy for cardiovascular diseases and cancer is the development of effective vec-
tors for catheter-based gene delivery. Although adenoviral vectors have proven effective for this purpose in 
animal models, the ability to achieve comparable gene transfer with nonviral vectors would provide poten-
tially desirable safety and toxicity features for clinical studies. In this report, w e describe the use of a 
new cationic DNA-liposome complex using an improved expression vector and lipid, A^-(3-aminopropyl)-
A^^-dimethyl-2,3-bis(dodecyloxy)-l-propaniminium bromide/dioleoyl phosphatidylethanolamine (GAP-DL-
R I E / D O P E ) to optimize catheter-mediated gene transfer in porcine arteries. The efficiency of this vector was 
compared to D N A alone, D N A with a previously described cationic liposome complex, ( ± )-A^-(2-hydrox-
yethyl)-A^^-dimethyl-2,3-bis(tetradecyloxy)-l-propanaminium bromide ( D M R I E / D O P E ) , and a replication-
defective adenoviral vector in a porcine artery gene transfer model. W h e n used in optimal ratios, G A P - D L -
R I E / D O P E liposomes provided a 15-fold higher level of gene expression in arteries compared to D N A alone 
or D M R I E / D O P E . Gene expression was observed in intimal and medial cells. However, when compared to 
adenoviral vectors (10^" pfu/ml), gene expression following G A P - D L R I E / D O P E transfection was ~20-fold 
lower. Following intravenous injection of G A P - D L R I E / D O P E in mice, biochemical, hematological, and 
histopathological abnormalities were not observed. Significant improvements in the efficacy of arterial gene 
expression can be achieved by optimization of transfection conditions with DNA-liposome complexes in vivo 
that m a y prove useful for arterial gene delivery in cardiovascular diseases and cancer. 
OVERVIEW SUMMARY INTRODUCTION 
GAP-DLRIE/DOPE, a new cationic liposome preparation, /^ ene transfer into the arterial wall has the potential to alter 
is an efficient liposomal vector that increases gene expres- V J t h e biological response of vascular cells to growth stimu-
sion in arteries compared to naked D N A or previously de- lation, lipid accumulation, coagulation, and inflammation, all 
scribed cationic DNA-liposome complexes hy more than 15- of which may contribute to the development of cardiovascular 
fold. Although less efficient than adenoviral gene transfer, diseases. Large arteries also provide access to microvessels of 
these levels of gene expression represent a significant im- organs and malignant neoplasms for recombinant gene trans-
provement in liposome transfection in vivo and approach fer. An important objective of arterial gene transfer is the de-
levels observed vnth cUnically acceptable doses of adenovi- velopment of effective vectors that optunize gene expression 
ral vectors. The improvement in gene expression, together and minimize toxicity. Previous studies have demonstrated the 
with the relative safety associated with liposomal gene trans- feasibility of arterial gene delivery in vivo with viral and non-
fer, suggests that such nonviral vectors may he appropriate viral vectors (for review, see Nabel, 1995). Side-by-side com-
for' human gene therapy protocols which utilize catheter- parisons of nonviral and viral vectors have not been made, and 
based sene delivery. " '̂  currently accepted fliat adenoviral vectors result in higher 
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levels of gene expression in vivo compared with nonviral vec-
tors. Although adenoviral vectors are efficient vectors, stadies 
have suggested a greater potential for local and systemic toxi-
cities in some organs, like the lung (Simon et al, 1993), par-
ticularly at the high concentrations often needed for optimal ef-
ficacy. This concem has been highlighted recenfly in human 
gene therapy protocols for cystic fibrosis (Rnowles etal, 1995). 
A n attractive, altemative approach to gene delivery to arteries 
is cationic DNA-liposome complexes (Nabel et al, 1990; 
Chapman et al, 1992). These vectors have been employed in 
preclinical animal models and clinical gene therapy studies in 
diverse cell types, including those in the vasculature (Leclerc 
et al, 1992; E. Nabel et al, 1993; Shi et al, 1994; Muller et 
al, 1994), airway epithelium (Caplen etal, 1994), and tamors 
(G. Nabel et al, 1993). 
Several featares of these nonviral vectors are aflractive for 
gene transfer studies, including their relative safety and lack of 
toxicity. However, a limitation of these vectors has been a rel-
ative inefficiency of gene transfer. In this study, we describe 
the application of a cationic lipid, GAP-DLRIE/DOPE, for ar-
terial gene transfer in vivo. Stadies were performed to deter-
mine optimal DNA:lipid ratios and concentrations for gene 
transfer in vivo and to compare its efficiency to D N A alone, 
other cationic lipids, and adenoviral vectors. The safety and tox-
icity of this lipid formulation was also analyzed in vivo after 
systemic intravenous injection in mice. Here, we describe sub-
stantial improvements in transgene expression with cationic 
DNA-liposome complexes that may improve their utUity for 
catheter-based gene delivery. 
MATERIALS AND METHODS 
Plasmid expression vectors and cationic lipids 
A eukaryotic expression vector plasmid encoding a chlo-
ramphenicol acetyl transferase (CAT) gene under the control of 
a cytomegalovirus promoter and enhancer, p C M V - C A T , was 
used for in vivo experiments. This plasmid contains a 5' un-
translated region and intron sequences from the C M V immedi-
ate early gene downstream ofthe promoter and a bovine growth 
hormone polyadenylation signal (Manthorpe et al, 1993). A 
plasmid expression vector encoding a heat-stable human pla-
cental alkaline phosphatase (hpAP) gene was constructed using 
flie same plasmid backbone (VR1012), pCMV-hpAP. The 
blunted Hind UI, Pst I hpAP fragment from pBlueScript was 
cloned in the blunted Sal I site of VR1012. Plasmid D N A was 
prepared by column chromatography (Hom et al, 1995; Lew 
et al, 1995) and kindly supplied by Vical, Inc. For the highest 
concentration of plasmid D N A used, the maximum total endo-
toxin was ~ 240 Eu. 
For in vivo, experiments, the following experimental groups 
were stadied: (i) plasmid D N A alone with no vector: (ii) plas-
mid D N A complexed witii DMRIE/DOPE; and (iii) plasmid 
D N A complexed with GAP-DLRIE/DOPE. DMRIE/DOPE 
was prepared as previously described (Wheeler et al, 1996). 
GAP-DLRIE/DOPE is ( ± )-A?-(3-aminopropyl)-/Vf,A?-dimethyl-
2, 3-(te-dodecyloxy)-l-propaniminium bromide, complexed in 
a 1:1 mole:mole mixtare with DOPE, -a-dioleoyl phos-
phatidyleflianolamine (Feigner et al, 1994). GAP-DLRIE is a 
member of the 2,3-dioxy-propaniminium class of cationic 
lipids, which includes D M R I E , D O T A P , D O T M A , and 
DOSPA. This class of cytofectins has two hydrophobic chains 
appended to a quatemary ammonium moiety via a polar dioxy-
propyl group. The lipophilic region of GAP-DLRIE is com-
prised of two linear, fully saturated 12-carbon alkyl chains, and 
the quatemary ammonium group bears a propylamine substi-
tation. Transfection efficiency of flie 2,3-dioxy propaniminium 
class of cationic lipids is enhanced by admixing with D O P E . 
To determine the optimal ratios of GAP-DLRIE/DOPE to 
plasmid D N A , p C M V - C A T was complexed with G A P -
DLRIE/DOPE at increasing concenti-ations of 6.25 /tg/ml to 
600 /ig/ml (20.15 to 1613 p M ) whereas the D N A was held 
constant. To quantitate the stoichiometiy of cationic lipid and 
D N A interaction, the molar ratio of cationic lipid to nu-
cleotide, rather than cationic lipid to plasmid, was calculated 
based on the molecular weight of a single nucleotide (310 
grams/mole). Likewise, to assess the optimal concentrations 
of GAP-DLRIE/DOPE, the lipid was complexed with plasmid 
D N A at increasing concentrations of 105, 158, 316, and 526 
p M , whereas the D N A concentration was held constant at 125 
/ig/ml (404 p M ) to yield progressively increasing cationic 
lipid/DNA ratios of 0.26, 0.39, 0.78, and 1.3 molar. Once an 
optimal ratio of GAP-DLRIE/DOPE:DNA was chosen, the ab-
solute concentration of cationic lipid:nucleotide was held con-
stant and increasing concentrations of D N A from 6.25 to 600 
pg/ml (20.15 to 1613 p M ) were tested. The p C M V - C A T ex-
pression vector was used to determine optimal ratios and con-
centrations for arterial gene transfer. The p C M V - h p A P vec-
tor was used to determine cellular localization of the transgene 
following arterial gene transfer. D M R I E / D O P E (310 p M ) 
complexed with D N A (403 p M , 125 pg/ml), which had been 
previously optimized in endothelial and smooth muscle cells 
in vivo (San et al, 1993), and plasmid D N A (806 p M , 250 
/ig/ml) in the absence of lipid was compared to the optimal 
formulation of GAP-DLRIE/DOPE:DNA. For preparation of 
cationic liposome-DNA complexes, D N A was diluted in 0.4 
ml of Opti-MEM (GIBCO, B R L ) at room temperature. G A P -
DLRIE/DOPE was resuspended in sterile water, flien diluted 
in 0.4 ml of Opti-MEM. The lipids were added to D N A by 
gentie mixing. D M R I E / D O P E was complexed with D N A in 
lactated Ringer's solution as previously described (San et al, 
1993). For in vivo toxicity studies, a plasmid encoding H L A -
B7 and ft microglobulin (G. Nabel et al, 1993) under con-
trol of the Rous sarcoma vims long terminal repeat was used. 
For the toxicity studies in mice, GAP-DLRIE/DOPE:DNA 
complexes were prepared by mixing plasmid D N A (10 /tg) 
with GAP-DLRIE/DOPE (30 pg) in a final volume of 0.1 ml 
of Ringer's solution before injection into the tail vein. 
Adenoviral vectors 
A recombinant adenovhal vector, ADV-CAT, was con-
structed by homologous recombination between sub360 ge-
nomic D N A , an Ad-5 derivative, and a C A T expression plas-
mid, pAd-CAT, which contains the same regulatory elements 
as the p C M V - C A T plasmid used for liposomal transfection 
stadies. The pAd-CAT plasmid was prepared by ligating a Msc 
1-Xmm I fragment from the p C M V - C A T expression vector into 
flie Bgl n site of a pAd-Bgl II plasmid. Human embryonic kid-
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ney 293 cells were co-ti-ansfected wifli 10 /tg of the Nhe I-di-
gested p A d - C A T and 1 /tg of Cla I and Xba I-digested sub360 
D N A . Infectious viruses were isolated by plaque assay, and 
plaques containing recombinant adenovirus were screened for 
C A T activity. The stmctare of the virus was confirmed by 
Soufliem blot analysis. The recombinant vims was propagated 
in 293 cells and purified as described (Davidson et al, 1993). 
Cesium chloride-purified vuus was dialyzed against phosphate-
buffered saline (PBS) and diluted for storage in 1 3 % glycerol-
P B S solution to yield a final concenti-ation of 10'^ viral parti-
cles/ml [10'° plaque forming units (pfu)/ml, determined by 
plaque assays]. All stocks were sterilized witii a 0.45-/tM fil-
ter and evaluated for the presence of replication-competent ade-
novmis by infection at a multiplicity of infection (moi) of 10 
onto 3T3 cells. None of the stocks used in these experiments 
yielded replication-competent vims. 
In vivo gene transfer 
Male and female Yorkshire pigs (n = 33) were used for in 
vivo experiments. Arterial gene transfer was performed in the 
right and left iliofemoral arteries of each pig as described (Nabel 
et al, 1990). Briefly, after anesthesia, the right and left il-
iofemoral arteries were exposed by surgical technique, and a 
double-balloon catheter (USCI, Billerica, M A ) was positioned 
in each artery. Gene transfer was performed into injured arter-
ies (n = 59), noninjured arteries {n = 6), and saline alone was 
infused in one injured artery as a control. Gene transfer into in-
jured arteries is a standard animal model of vascular gene trans-
fer for primary vascular diseases, such as atherosclerosis or 
restenosis (Ohno et al, 1994; Chang et al, 1995a). Gene trans-
fer into noninjured arteries might be performed in a clinical set-
ting, such as cancer gene therapy, to treat lesions withui an or-
gan by catheter-mediated gene delivery (Nabel et al, 1994). 
Arterial injury was performed by positioning the distal bal-
loon in the arterial site to be injured and inflating the balloon 
to 500 m m H g for 1 min. The balloon was deflated, and the 
catheter was repositioned such that the central portion of flie 
catiieter between flie two balloons stiaddles the injured area of 
flie artery (Simari et al, 1996b). In bofli injured and noninjured 
arteries, the arterial segment was flushed with the vector solu-
tion (0.8 ml), and bofli the proxunal and distal balloons were 
inflated. The vector solution was uistilled into the site of injury 
for 20 m m at 150 m m H g . Following instillation, flie caflieter 
was removed, and the animal recovered. Liposomal gene trans-
fer was performed in 49 arteries, D N A alone was mfused into 
seven arteries, and adenoviral gene transfer was conducted in 
three arteries using vkal titers of 1 X IO'" pfu/ml (total dose of 
7 X 10' pfu). Saline alone was infused into the central portion 
of flie double-balloon catheter after balloon injury in one artery. 
Liposome gene transfer was performed into six noninjured ar-
teries. 
Anunals were sacrificed 48 hr later. Following anestiiesia, 
the artery segment between flie two balloons was removed. Each 
artery sample (1 cm) was processed in an analogous manner by 
serial section into three rings. The middle section was fixed m 
1 0 % buffered formaldehyde, embedded in paraffm, and stamed 
with hematoxylin and eosin. The proxunal and distal sections 
were processed for protem extraction and measurement of C A T 
activity. All animal stadies were perfonned within the guide-
lines of the National Institates of Health and with the approval 
of flie University of Michigan Committee on the Use and Care 
of Animals. 
CAT assay 
Detection of CAT activity was performed as previously de-
scribed (Gorman et al, 1982). Forty-eight hours after transfec-
tion, the arteries were removed. Tissues were crushed using a 
glass pestle, then frozen and thawed three times. The samples 
were incubated 10 min at 65°C to inactivate deacetylase. 
Proteins were extracted and quantified by means of a colori-
metric assay (Bio-Rad, Hercules, C A ) . Ten to 200 /tg of pro-
tein from each artery was assayed for C A T activity during a 4-
hr incubation period. 
Histochemistry, immunohistochemistry, 
and morphometry 
Expression of recombinant hpAP protein was detected by 
histochemical analysis of transfected arteries (Pompili et al, 
1995). Formalin-fixed, paraffin-embedded specimens were sec-
tioned, placed in phosphate-buffered saline (PBS) at 65°C for 
60 min to inactivate endogenous alkaline phosphatase, and in-
cubated in a chromogenic substrate consisting of 5-bromo-4-
chloro-3-indolyl phosphate p-toluidine (1 mg/ml) and nitro blue 
tetrazolium chloride for 19 hr. Sections were counterstained 
Net Charge: Negative Positive 
e 20 
[GAP-DLRIE]: 0 105 158 316 526 
[Nucleotide]: 403 403 403 403 403 
Lipid:Nuc. ratio: 0 0.26 0.39 0.78 1.3 
Electrovalent ratio: 0 0.52 0.78 1.56 2.6 
FIG. 1. Gene expression in porcine arteries after transfection 
with a constant amount of p C M V - C A T plasmid D N A and in-
creasing lipid/nucleotide ratios. Plasmid D N A , 403 p M nu-
cleotide (125 /tg/ml), was incubated with 105 p M (125 /tg/ml, 
n = 5 arteries), 158 p M (187.5 /tg/ml, n = 4 arteries), 316 p M 
(375 /ig/ml, n = 6 arteries), and 526 p M (625 /tg/ml, n = 3 ar-
teries) of GAP-DLRIE, giving the indicated molar ratios of 
cationic lipid to nucleotide (Lipid:Nuc. ratio:) and charge ratio 
of lipid to nucleotide (Electi-ovalent ratio:). Naked D N A at the 
same concentration is included in comparison. Overall charge 
of the cationic DNA-liposome complex is shown above. 
Concentrations of lipid and nucleotide are indicated in p M . 
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FIG. 2. Reporter gene expression in porcine arteries with 0.26 (A) or 0.78 (B) molar ratio of GAP-DLRIE/DOPE:nucleotide 
and increasmg concentrations of DNA-liposome complex. Concentrations of lipid and nucleotide (pM) are shown, n = 3-6 ar-
teries at each lipid/nucleotide ratio. *p < 0.01, A N O V A witii the Scheffe test. 
with methylene green. Immunohistochemical studies were per-
formed to identify endothelial cells [monoclonal goat anti-
human von Willebrand's factor (vWf) antibody, 1:10,000 dilu-
tion, Atleuitic Antibodies] and smooth muscle cells (monoclonal 
mouse anti-smooth muscle a-actin antibody, 1:500 dilution, 
Boehringer Mannheim Biochemical) as previously described 
(Pompili et al, 1995). Measurements of transfection efficiency 
were made by counting the number of alkaline phosphatase-
positive cells and the total number of cells in the intima, me-
dia, and adventitia of arteries using a microscope-based video 
image analysis system (Image One Systems, Universal Imaging 
Corp.) as described (Pompili et al, 1995). 
Toxicity studies 
Intravenous injections were carried out via the tail vein us-
ing a 21-gauge needle in 24 adult female mice (strain BALB/c) 
to evaluate the tissues and systemic effects of G A P 
DLRIE/DOPE and D N A . For intravenous injections, G A P 
DLRIE/DOPE (30 /tg) and p C M V - C A T or HLA-B? plasmid 
D N A (10 pg) were mixed in a fmal volume of 0.1 ml of 
Ringer's solution immediately prior to injection. Three groups 
were stadied. In group 1, a single tail vein injection was given 
(n = 4 mice). Animals were sacrificed 4 days later, and heart, 
lung, kidney, and spleen were analyzed for percent C A T con-
version. In group 2, a single tail vein injection was given (n = 
10 mice). Animals were sacrificed 2 weeks later. Blood was 
collected pretreatment and at sacrifice and analyzed biochemi-
cally. Organs (brain, lung, heart, liver, kidney) were removed 
at 2 weeks for histopathology analysis. In group 3, a single tail 
vein injection was given at 2-week intervals for a total of three 
injections over 6 weeks, and animals were sacrificed at 6 weeks 
(/! = 10 mice). Blood was collected before treatment and 6 
weeks later for biochemical analysis. Organs were removed at 
6 weeks and analyzed by histology. 
Statistics 
Results are expressed as a mean and standard error of the 
mean (± SEM). Each artery was treated as an independent ob-
servation. The mean of each treatment group was compared by 










Lipid:Nuc. ratio 0.78 
FIG. 3. Comparison of gene expression at 0.26 and 0.78 p M 
ratios of GAP-DLRIE/DOPE and nucleotide. Left, n = 5 arter-
ies. Right, n = 4 arteries. Concentrations of GAP-DLRIE/ 
D O P E and nucleotide are indicated in p M . *p < 0.001; un-
paired, two-tailed Student's f-test. 
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ance (ANOVA) followed by a Scheffe test. If the ANOVA 
demonstrated a p < 0.05, then a 2 X 2 comparison was per-
formed using an unpahed, two-tailed Student's f-test to deter-
mine the level of significance accounting for multiple compar-
isons. 
RESULTS 
Optimization of the ratio of GAP-DLRIE/DOPE 
to DNA 
To determine the optimal ratio of lipid to DNA for arterial 
transfection, a plasmid expression vector encoding C A T regu-
lated by a C M V enhancer/promoter (pCMV-CAT) was trans-
fected into porcine arteries in vivo with GAP-DLRIE/DOPE. 
Increasing concentrations of GAP-DLRIE at the following 
doses: 105 p M (125 pg/ml), 158 p M (187.5 pg/ml), 316 p M 
(375 /tg/ml), and 526 p M (625 /tg/ml) and D O P E , at an 
equimolar concentration, were tested with D N A held constant 
at 403 p M nucleotide (125 /tg/ml), resulting in cationic 
lipid/nucleotide ratios of 0.26, 0.39, 0.78, and 1.3 molar. 
Control experiments were performed with D N A at the same 
concentration (403 p M ) without lipid. Measurements of C A T 
activity were made in extracts from transfected iliofemoral ar-
teries 48 hr later. Transfection with p C M V - C A T without lipid 
resulted in 5.0 ± 3.5% C A T conversion (Fig. 1). With this con-
stant amount of D N A (403 p M ) and increasing lipid concen-
tiations, C A T activity ranged from 4.75 ± 1 % to 24.5 ± 19.6%. 
The highest levels of gene expression were observed at 0.26, 
0.78, and 1.3 molar lipid/nucleotide ratios. The charge ratio for 
each cationic lipid/nucleotide ratio is also shown (Fig. 1). 
Because there are two positive charges per molecule of GAP-
DLRIE at physiological pH, the electrovalent ratio is two times 
higher than the lipid/nucleotide ratio. 
Optimization of the concentration of 
G A P - D L R I E / D O P E and D N A 
To examine the effect of flie concentration of GAP-DL-
RIE/DOPE and D N A complex on transfection efficiency in vivo, 
two lipid/nucleotide molar ratios were examined, 0.26 and 0.78. 
There were no significant differences in percent C A T conversion 
with increasing GAP-DLRIE/DOPE:nucleotide concentrations at 
a 0.26 ratio (p = NS) (Fig. 2A). In contrast, at a 0.78 ratio, hi-
creasing the concenfration of GAP-DLRIE/DOPE:nucleotide re-
sulted in a dose-dependent increase in gene expression, with max-
imal C A T activity reached wifli 631 p M (750 /tg/ml) 
B C 
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Pir 4 Alkaline ohosohatase expression in endoflielial and smootii muscle cells in ttansfected porcine arteries. Microscopic 
fectioi w ^ S z e d S histocheLal staining in arteries ttansfected wifli GAP-DLRffi/DOPE and p C M V - C A T (A) or p C M V -
hoAP ffi C) hmiiunohistochemical analysis was perfonned witii a monoclonal antibody for yon Wfllebrand s factor (D) or smoofli 
muscle a-actm (E), identifying transfected cells as endothelial cells and smoofli muscle cells. 
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Table 2. Evaluation of Serum Enzymes Pre and 6 Weeks Post Three Intravenous Tail Vein 
Injections of Saline (Control) or GAP DLRIE/DOPE and DNA (Experimental) in Mice 
Albumin (g/dl) 
Alkaline phosphatase (IU/1) 
Amylase (U/1) 
Bilirubin (mg/dl) 










S G O T (lU/1) 
SGPT (lU/1) 
Triglycerides (mg/dl) 
Total protein (G/dl) 
Total globulin (g/dl) 
Confro/ 
fre 
fn = 5 ) 
2 5 + 0.2 
185 •+• 9 
2559 + 102 
0.6 + 0.2 
22 + 2 
7.6 + 0.5 
109 + 3 
88 + 9 
0.5 ± 0.1 
23 + 3 
181 ± 20 
160 ± 3 
7.5 ± 0.9 
5.8 ± 0.4 
77 ± 3 
26 ± 5 
112 ± 13 
4.9 ± 0.5 












































fn = 5 ) 
2.3 ± 0.2 
165 + 16 
2385 ± 60 
0.5 ± 0.1 
22 ± 1 
7.0 ± 0.4 
119 + 3 
76 ± 9 
0.4 ± 0.1 
21 ± 4 
231 ± 30 
164 ± 2 
8.3 ± 0.8 
7.0 + 0.5 
57 ± 5 
21 ± 2 
84 ± 12 
4.1 ± 0.2 
1.8 ± 0.2 
'xperimental 
Post 
(n = 5 ) 
2.6 + 0.1 
131 ± 11 
2534 ± 130 
0.1 + 0.1 
21 ± 2 
9.0 ± 0.2 
115+1 
72 ± 4 
0.3 ± 0.2 
21 ± 1 
153 ± 12 
149 ± 1 
6.7 ± 0.3 
4.3 ± 0.3 
69 ± 21 
13 + 2 
65 ± 11 
4.2 ± 0.2 
1.3 ± 0.1 
Data are expressed as mean ± SEM. 
plexes used. In previous studies, high concentrations of 
DNA-liposome complexes led to aggregation and toxicity fol-
lowing intravenous injection in mice in vivo (Stewart et al, 
1992). Newer formulations have proven less toxic, allowing 
concentrations up to 1,000-fold higher than those used previ-
ously (San et al, 1993). When using the 0.78 molar ratio, in-
creasing concentrations of lipid and D N A produce a dose-re-
sponse curve that reached an optimum at 803 p M D N A . The 
decrease in transfection efficiency at higher concentrations 
may be the result of aggregation of the complexes, given the 
high amount of lipid used. Although it is possible that the 
DNA-liposome complex could exert a toxic effect on arter-
ial cells, we did not observe increased toxicity in arteries 
transfected with GAP-DLRIE/DOPE compared with arteries 
Table 3. Histological Analysis of Tissue Following Introduction of DNA-Liposomes In Vivo 
Number of injections: 





















































Control injection (lactated Ringer's solution) or DNA-liposome complex (GAP-DLRIE/DOPF^ + D N a 
were performed as described in Tables 1 and 2 legends wi-'wrE,; -i- uina 
nolSignSiaS"" ""^ °'""^' " °"^ °' *^ ''^^ ^^""P'^^^ *-^ - --- Pa^ologic changes of 
''No data are available for one of the five samples. 
"̂ A rare cluster of mononuclear inflammatory cells was observed in one of thP fi,,» i 
minor pathologic changes of no clinical significance. *' ̂ '̂ ^ '^^P'^'^ *ese are 
''There was no ovary in one of the five samples. 
"̂ One of the five samples of Fallopian tube displayed verv acute inflamm̂ fr̂ ,., • ru 
this pathology is unlikely to be related to the treatment. '"flammatory infiltrate without necrosis; 














FIG. 6. Comparison of percent C A T conversion in ttans-
fected arteries with optunal concenttations followmg adenovi-
ral mfection (7 X 10' pfu) and GAP-DLRIE/DOPE and D N A 
(0.78 molar ratio), n = 3 arteries in each group *p < 0.001, un-
paired, two-tailed Student's f-test. 
and D N A causes toxicity to major organ systems in vivo, semm 
biochemical parameters and histopathology were evaluated in 
three groups of mice. In group 1 (n = 4 mice), C A T activity 
was detected in spleen, but not heart, lung, or kidney, 4 days 
after a single inttavenous tail vein injection of GAP-
DLRIE/DOPE (30 pg) and D N A (10 pg). hi group 2 (n = 10 
mice), sahne or GAP-DLRIE/DOPE (30 pg) and D N A (10 /tg) 
was injected into the tail vein and serum biochemistries and 
histopathology were examined 14 days later. No significant dif-
ferences in semm enzymes were observed pre- and post-tteat-
ment in either group, and major organ pathology was not pre-
sent (Tables 1 and 3). In group 3 (« = 10 mice), smgle injections 
of saline or GAP-DLRIE/DOPE (30 /tg) and D N A (10 /tg) were 
given at 2-week intervals for 6 weeks (three injections total). 
Semm biochemical abnonnalities and major organ pathology 
were not observed (Tables 2 and 3). 
D I S C U S S I O N 
In this stady, we have evaluated and determined an optimal 
lipid/nucleotide ratio and concenttation of a new cationic lipid, 
GAP-DLRIE/DOPE, for arterial gene ttansfer in vivo. W e found 
that ttansfection of arteries with a 0.78 molar ratio of GAP-DL-
RIE/DOPE (631 pM, 750 /tg/ml) and nucleotide (806 pM, 250 
/tg/ml) resulted in an approximate 15-fold higher level of C A T 
activity compared with D N A alone or another cationic lipid, 
DMRIE/DOPE. However, when compared with adenoviral vec-
tors (7 X 10' pfu), C A T activity with GAP-DLRIE/DOPE and 
D N A was approximately 20-fold less. No significant biochem-
ical abnormalities or organ toxicities were observed following 
inttavenous injection of GAP-DLRIE/DOPE and DNA. This 
new cationic lipid formulation, when optimized for gene ttans-
fer efficiency in vivo, provides a significant improvement in 
gene expression compared with other nonviral vectors and be-
gins to approach the range of efficacy observed with adenovi-
ral vectors (titers s 10' pfu/ml). 
One of the limitations of lipsome-mediated gene transfer 
is the relatively low concenttation of DNA-liposome com-
Table 1. Evaluation of Serum Enz-̂ tvies Pre and 14 Days Post a Single Intravenous Tail Vein 
Injection of Saline (Control) or G A P DLRIE/DOPE and D N A (Experimental) in Mice 
Albumin (g/dl) 
Alkaline phosphatase (IU/1) 
Amylase (U/1) 
Bilimbin (mg/dl) 










S G O T (IU/1) 
SGPT (IU/1) 
Triglycerides (mg/dl) 
Total protem (G/dl) 
Total globulin (g/dl) 
Pre 
(n=5) 
2.5 ± 0.2 
155 + 14 
2511 ± 216 
0.6 + 0.2 
20 ± 2.4 
6.6 ± 0.4 
109 ± 2.5 
94 ± 5 
0.4 ± 0.08 
27 + 2.4 
183 + 14 
160 ± 3 
9.3 ± 1.2 
8.8 ± 1.0 
89 ± 11 
38 ± 4 
106 ± 7 
4.1 ± 0.3 























































































3.2 ± 0.2 
143 ± 8 
2372 ± 76 
0.6 + 0.1 
20.4 + 2 
9.5 ± 0.4 
119 ± 1.0 
63 ± 6 
0.7 ± 0.02 
24 ± 2.0 
155 + 10 
159 ± 1 
5.9 ± 0.4 
4.3 ± 0.1 
99 ± 25 
18 ± 1 
77 ± 3 
4.3 ± 0.2 
1.1 ± 0.2 
Data are expressed as mean ± SEM. 
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